90-Day toxicological evaluation of BLX-1002, a novel anti-diabetic compound in rats

被引：0
|
作者：
Nag, A
Bhatnagar, U
Sen, AP
Neogi, P
Dey, D
Nag, B
机构：
[1] Bexel Pharmaceut Inc, Union City, CA 94587 USA
[2] Orchid Pharmaceut & Pharmaceut Ltd, Madras 600119, Tamil Nadu, India
来源：
FASEB JOURNAL | 2005年 / 19卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A828 / A828
页数：1
相关论文
共 50 条
  • [1] In vitro and In vivo activities of the major metabolite of a novel anti-diabetic compound BLX-1002
    Gutala, S
    Gupta, A
    Pandey, B
    Nag, A
    Nag, B
    Dey, D
    FASEB JOURNAL, 2004, 18 (04): : A608 - A609
  • [2] Identification and characterization of the major metabolite of BLX-1002, a novel orally active anti-diabetic compound
    Gutala, S
    Nag, A
    Balse, P
    Neogi, P
    Nag, B
    Dey, D
    FASEB JOURNAL, 2004, 18 (04): : A605 - A605
  • [3] Toxicological evaluation of an anti hyperglycemic compound BLX-1002 approaching to clinical trials
    Nag, A
    Moon, H
    Gutala, S
    Neogi, P
    Agarwal, SK
    Dey, D
    Nag, B
    DIABETES, 2004, 53 : A139 - A139
  • [4] Amino acid conjugated, orally active, novel anti-diabetic compound BLX-1002 has no affinity to PPARγ
    Dey, D
    Pandey, B
    Nag, A
    Neogi, P
    Nag, B
    DIABETES, 2004, 53 : A483 - A483
  • [5] Single dose pharmacokinetics and bioavailability of BLX-1002 - A novel anti dibetic compound in rats
    Nag, A
    Dey, D
    Gutala, S
    Neogi, P
    Pandey, B
    Nag, B
    FASEB JOURNAL, 2004, 18 (04): : A605 - A605
  • [6] Novel anti-diabetic compound BLX-1002 with no affinity to PPARα, γ and δ, lowers serum triglyceride levels and systolic blood pressure in fructose fed rats
    Dey, D
    Chovatia, M
    Nag, A
    Pandey, B
    Nag, B
    DIABETOLOGIA, 2004, 47 : A256 - A257
  • [7] Pharmacokinetics and bioavailability of BLX-1002 - A single amino acid conjugated anti diabetic compound in dogs
    Nag, A
    Neogi, P
    Dey, D
    Pandey, B
    Gutala, S
    Nag, B
    FASEB JOURNAL, 2004, 18 (04): : A605 - A606
  • [8] BLX-1002:: A new class of orally-active anti-diabetic small molecule with no PPAR-γ affinity
    Pandey, B
    Nag, A
    Singh, A
    Vargas, H
    Gutala, S
    Dey, D
    Nag, B
    DIABETES, 2003, 52 : A143 - A143
  • [9] BLX-1002:: A non-adipogenic and Non-PPARγ agonist anti-diabetic compound which inhibits TNFα and IL-6 Cytokines
    Dey, D
    Gupta, A
    Nag, A
    Pandey, B
    Vargas, H
    Sriram, S
    Nag, B
    DIABETES, 2003, 52 : A141 - A141
  • [10] A 90-day toxicological evaluation of compound 1080 (sodium monofluoroacetate) in Sprague-Dawley rats
    Eason, CT
    Turck, P
    TOXICOLOGICAL SCIENCES, 2002, 69 (02) : 439 - 447
12345